Comprehensive food allergy test

• US 20050255533A1
• Filed: 02/09/2005
• Published: 11/17/2005
• Est. Priority Date: 02/10/2004
• Status: Abandoned Application

• Current Assignee: Brendan BioScience, LLC
• Original Assignee: Brendan BioScience, LLC
• Inventors: Dorval, Brent L., Dantini, Daniel C.
• Application Number:
  US11/053,680
• Publication Number:
  US 20050255533A1
• Time in Patent Office: Days
• US Class Current: 435/7.920
• CPC Class Codes: G01N 2800/24 Immunology or allergic disorders
• CPC Class Codes: G01N 33/537 with separation of immune complex from unbound antigen or antibody
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/6854 Immunoglobulins

Abstract

The present invention relates to methods and devices for detecting biological entities and components associated with hypersensitivity reactions in patients with food allergies. Specifically, the assays of the invention are capable of qualitatively and/or quantitatively measuring IgG, IgA, IgM and/or IgE antibodies and immunocomplexed C3b (IC-C3b) produced as a result of exposure to food.

Claims

1. A kit for determining the presence of allergen-specific immunoglobulins and immuncomplex C3b (IC-C3b) in a biological sample comprising:

(a) a solid support comprising an immobilized allergen that is to be exposed to a biological sample thereby binding and immobilizing allergen-specific immunoglobulins and immuncomplex C3b; and

(b) at least two labeled binding partners;

(i) a first labeled binding partner that specifically binds the immobilized allergen-specific immunoglobulins; and

(ii) a second labeled binding partner that specifically binds the immobilized immunocomplex C3b.

2. The kit of claim 1 wherein said biological sample is serum or saliva.

3. The kit of claim 1 wherein said solid support is a microtiter dish well.

4. The kit of claim 1 wherein said first labeled binding partner is selected from the group consisting of labeled anti-human, anti-IgG, anti-IgA, and anti-IgM antibodies and said second labeled binding partner is an anti-C3d antibody.

5. The kit of claim 1 wherein said first labeled binding partner is anti-IgG antibody and said second labeled binding partner is an anti-C3d antibody.

6. The kit of claim 1 wherein said label is part of a signal producing system.

7. The kit of claim 1 wherein the amount of label immobilized on the solid support can be read quantitatively.

8. The kit of claim 1 wherein the allergen is derived from the group consisting of milk, corn, shrimp, lobster, crab, peanuts, walnuts, fish, eggs, soy and wheat.

9. The kit of claim 1 wherein the allergen is selected from the group consisting of monosodium glutamate (MSG), gluten, casein, β

-lactoglobulin and bovine serum albumin.

10. A method of determining the presence of allergen-specific immunoglobulins and immuncomplex C3b (IC-C3b) in a biological sample comprising:

(a) exposing a solid support comprising an immobilized allergen to a biological sample;

(b) washing unbound molecules from the biological samples from the solid support;

(c) exposing said solid support to at least two labeled binding partners;

(i) a first labeled binding partner that specifically binds the immobilized allergen-specific immunoglobulins; and

(ii) a second labeled binding partner that specifically binds the immobilized immuncomplex C3b;

(d) washing unbound labeled binding partners from the solid support;

(e) detecting the presence of label bound to the solid support; and

correlating it with the presence of allergen specific IC-C3b and allergen specific immunoglobulins in the biological sample.

11. The method of claim 10 wherein said biological sample is serum or saliva.

12. The method of claim 10 wherein said solid support is a microtiter dish well.

13. The method of claim 10 wherein said first labeled binding partner is selected form the group consisting of labeled anti-human, anti-IgG, anti-IgA, and anti-IgM antibodies and said second labeled binding partner is an anti-C3d antibody.

14. The method of claim 10 wherein said first labeled binding partner is anti-IgG antibody and said second labeled binding partner is an anti-C3d antibody.

15. The method of claim 10 wherein said label is part of a signal producing system.

16. The method of claim 10 wherein the amount of label immobilized on the solid support is be read quantitatively.

17. The method of claim 10 wherein the allergen is derived from the group consisting of milk, corn, shrimp, lobster, crab, peanuts, walnuts, fish, eggs, soy and wheat.

18. The method of claim 10 wherein the allergen is selected from the group consisting of monosodium glutamate (MSG), gluten, casein, β

-lactoglobulin and bovine serum albumin.

19. The method of claim 10 wherein:

A. a presence of allergen-specific IgE and a substantial lack of allergen-specific IgG, IgA, IgM and IC-C3b in the biological sample correlates with Type I hypersensitivity reactions;

B. a presence of allergen-specific IgG, IgA, and IgM and IC-C3b and a substantial lack of allergen-specific IgE in the biological sample correlates with Type II hypersensitivity reactions;

C. a presence of allergen-specific IgG and IC-C3b and a substantial lack of allergen-specific IgE, IgA, IgM in the biological sample correlates with Type I hypersensitivity reactions; and

D. a substantial lack of allergen-specific IgG, IgA, IgM and IC-C3b in the biological sample correlates with Type I hypersensitivity reactions.